Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
14 USD -0.43% Intraday chart for Novavax, Inc. -2.78% +191.67%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Novavax Files Emergency Use Authorization Amendment For Updated COVID-19 Vaccine MT
FDA asks COVID vaccine makers to target KP.2 strain with updated shots RE
Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine CI
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says RE
S&P 500, Nasdaq dip on the eve of US payrolls data RE
Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus RE
Novavax Says FDA Review Target Date Set for Covid-19 Vaccine Biologics License Application MT
Novavax Says It Can Deliver Recommended Covid Vaccine in September DJ
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says RE
Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Flu-Covid-19 Combination Vaccines CI
Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024 CI
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating MT
Novavax: 1st shipment of R21/MatrixM malaria vaccine CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... Our Logo
Focus on Nvidia Our Logo
Shah Capital ends campaign against Novavax board after Sanofi deal RE
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors MT
Shah Capital withdraws campaign against Novavax directors after Sanofi deal RE
Shah Capital withdraws campaign against three Novavax directors RE
Shah Capital Management Announces Withdrawal of Nominations CI
Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance MT
Chart Novavax, Inc.
More charts
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14 USD
Average target price
22.8 USD
Spread / Average Target
+62.86%
Consensus
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. News Novavax, Inc.
  5. US Equity Markets Close Mixed Friday After Consumer Sentiment Falls